KYLIE HARNESS: Open Payments
NPI 1033893565 · INDIANAPOLIS, IN. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$583 in 27 payments from 14 companies in 2025. Trend: 2023 $229 · 2024 $1,098 · 2025 $583
Food & beverage: $583
| Company | Payments | Amount |
|---|---|---|
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 6 | $122 |
| Theratechnologies Inc. | 3 | $75 |
| Otsuka America Pharmaceutical, Inc. | 4 | $73 |
| Axsome Therapeutics, Inc. | 3 | $69 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $36 |
| Gilead Sciences, Inc. | 1 | $31 |
| Seqirus USA Inc | 1 | $30 |
| Lundbeck LLC | 1 | $27 |
| Neurocrine BioSciences, Inc. | 1 | $26 |
| ABBVIE INC. | 1 | $20 |
Products named: CAPLYTA, REXULTI, EGRIFTA, Auvelity, TRINTELLIX, Epclusa, Flucelvax, INGREZZA.
Industry payments across IN — which companies pay providers there.
